Rituximab is an anti-CD20 monoclonal antibody that suppresses inflammation effectively in autoimmune diseases. It was initially approved by the FDA for the treatment of B-cell lymphomas and later ...

The predicted structure for the rituximab triple variant in complex with the CD20 peptide is shown in the figure above. The potent antitumor activity of the triple variant has potential as a ...